Gilead to support generic lenacapavir in low-income nations
Earlier this month, Gilead Sciences announced that it had signed non-exclusive, royalty-free voluntary licensing agreements…
Posted inConferences News Research Treatment
HIV viral rebounds following CRISPR gene therapy
EBT-101, a gene-editing therapy utilising CRISPR technology, showed promising safety and tolerability in an initial…
Posted inHealthcare Medicines News Parenting PrEP Prevention Research
Cabotegravir PrEP injection is safe during pregnancy
The safety and tolerability of long-acting injectable cabotegravir (CAB-LA) as HIV pre-exposure prophylaxis (PrEP) for…
Posted inConferences Cure News Treatment
Man “likely cured” of HIV after stem cell transplant
A new case of prolonged HIV remission was reported during the 25th International AIDS Conference…
Posted inConferences Healthcare Medicines News PrEP Prevention
Twice-yearly lenacapavir injection sees zero HIV infections in trial
AIDS 2024 Conference Coverage Preliminary findings from the phase III PURPOSE 1 trial revealed that…